ArticleFrontiers in psychiatry2024
Prevalence and correlates of post-stroke anxiety in Changde, China during 2023 following the lifting of COVID-19 restrictions.
Article in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Studies on post-stroke anxiety (PSA) following the lifting of COVID-19 restriction measures are currently lacking. We investigated the factors affecting PSA after full release of COVID-19 epidemic in China. Methods: Patients with stroke admitted to the First People's Hospital of Changde City from March 2023 to September 2023 participated in a questionnaire survey comprising a general demographic questionnaire, the Generalized Anxiety Scale-7. Additionally, data on the National Institutes of Health Stroke Scale, modified Rankin Scale, C-reactive protein (CRP), thyroid-stimulating hormone (TSH), homocysteine, TOAST classification, and the stroke site were collected, and the correlations between these indices and the mental health conditions of the patients were evaluated. Results: Among 947 patients, the incidence of PSA was 14.57%.PSA was not linked to prior COVID-19 infection. This study found that Sleep duration (P=0.01), hyperlipidemia (P=0.01), migraine (P=0.02), and family history of stroke (P=0.01) were associated with PSA. Conclusions: Our study found that the prevalence of PSA was 14.57%. In addition, sleep duration, hyperlipidemia, migraine and family history of stroke were independent risk factors for PSA following the lifting of COVID-19 restrictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.